Drug & intervention

risedronate

RxCUI 73056

Clinical trials6
Recruiting0
Related conditions8
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Risedronic acid

Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth. It was patented in 1984 and approved for medical use in 1998.

Read on Wikipedia ↗ Wikidata Q408724 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

6 shown
Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRTNCT03861091 · 2019-07-12
COMPLETED
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast CancerNCT00859703 · 2009-11-01
COMPLETED
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor TherapyNCT00485953 · 2007-09-01
COMPLETED
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate CancerNCT00426777 · 2007-01-01
COMPLETED
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal TherapyNCT00216060 · 2003-10-01
TERMINATED
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate CancerNCT00859027 · 2003-01-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.